Related Experiment Video
Updated: Jan 3, 2026

Author Spotlight: Investigating the Pathophysiology of Eosinophilic Esophagitis
Published on: May 10, 2024
Future therapies for eosinophilic gastrointestinal disorders
Robert D Pesek1, Sandeep K Gupta2
1Division of Allergy/Immunology, Department of Pediatrics, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Arkansas.
Novel therapeutics for eosinophilic gastrointestinal disorders (EGIDs) are advancing rapidly. Monoclonal antibodies targeting IL-4, IL-5, IL-13, integrins, and Siglec-8 show promise, alongside new corticosteroid formulations.
Area of Science:
- Gastroenterology
- Immunology
- Pharmacology
Background:
- Eosinophilic gastrointestinal disorders (EGIDs) represent a group of inflammatory conditions.
- Recent advancements have deepened the understanding of EGID pathophysiology.
- This has spurred the development of targeted therapeutic strategies.
Purpose of the Study:
- To provide a comprehensive review of novel therapeutics currently in development for EGIDs.
- To assess the progress and potential of emerging treatments.
Main Methods:
- A systematic literature search was conducted using PubMed.
- Clinical trial data was sourced from ClinicalTrials.gov.
- Studies focusing on EGID treatments and clinical trials were selected for review.
Main Results:
- Significant progress in understanding EGID mechanisms has led to novel therapeutic development.
- Monoclonal antibodies targeting IL-4, IL-5, IL-13, integrins, and Siglec-8 have demonstrated promise in early trials.
- Novel corticosteroid formulations are also under development.
Conclusions:
- The field of EGID research is rapidly evolving.
- Disease-modifying therapeutics are nearing clinical application for EGIDs.
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Barrett Esophagus-II: Clinical Manifestations and Management
To diagnose Barrett's esophagus, healthcare providers often recommend an endoscopy for those showing symptoms of acid reflux. The procedure...
Esophageal Strictures-II: Clinical Features and Management
Healthcare providers should gather a comprehensive medical history and conduct a physical examination for diagnosis. If esophageal stricture is...
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...

